FLT3 and acute myeloid leukemia: Most likely they will be administered in combination with standard chemotherapy and other molecularly targeted agents since the efficacy of FLT3 inhibitors against AML is less than optimal when administered alone but can significantly enhance the effectiveness of other forms of AML therapeutics when combined.